Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control

S. Akalin, K. Berntorp, A. Ceriello, A. K. Das, E. S. Kilpatrick, T. Koblik, C. S. Munichoodappa, C. Y. Pan, W. Rosenthall, M. Shestakova, B. Wolnik, V. Woo, W. Y. Yang, M. T. Yilmaz

Research output: Contribution to journalArticlepeer-review

Abstract

Background: There is compelling evidence showing that achieving good glycaemic control reduces the risk of microvascular complications in people with type 1 and type 2 diabetes. Likewise, there is clear evidence to show that achieving good glycaemic control reduces the risk of macrovascular complications in type 1 diabetes. The UKPDS 10-year follow up suggests that good glycaemic control also reduces the risk of macrovascular complications in type 2 diabetes. Despite this, recent results from ACCORD, ADVANCE and VADT present conflicting results and data from the ACCORD trial appear to suggest that very low HbA 1c targets (1c targets (

Original languageEnglish
Pages (from-to)1421-1425
Number of pages5
JournalInternational Journal of Clinical Practice
Volume63
Issue number10
DOIs
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control'. Together they form a unique fingerprint.

Cite this